← All trials
NCT06800248
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2025
- Primary completion
- Dec 31, 2025
- Completion date
- Feb 28, 2026
- First posted
- Jan 29, 2025
- Last posted
- Feb 10, 2025
- Enrollment
- 315
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of BaselLead sponsor
- University of BaselOfficial
- BayerCollaborator
- University of the PhilippinesCollaborator
- Silicon Valley Community FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.